Axela Licenses Proteome Sciences' Brain Damage Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it has inked a licensing deal that permits Axela to develop assays that measure Proteome Sciences' brain damage biomarkers on Axela's multiplex biomarker assay dotLab system.

The agreement includes an option for Axela to license the developed assays for research and diagnostic uses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.